MedTrace Logo

Application of hybridAPC in the Treatment of Barrett

NCT03418584 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2018-02-01

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of the new technique of HybridAPC in the treatment of Barrett.

Conditions

  • Barrett's Esophagus

Interventions

DEVICE

HybridAPC

HybridAPC is a device which combines submucosal fluid injection with APC

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    collaborator OTHER

  • First Affiliated Hospital of Zhejiang University

    collaborator OTHER

  • The First Affiliated Hospital of Soochow University

    collaborator OTHER

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    collaborator OTHER

  • Shanghai Tongji Hospital, Tongji University School of Medicine

    collaborator OTHER

  • Taizhou Hospital

    collaborator OTHER

  • Changhai Hospital

    lead OTHER

Principal Investigators

  • Zhaoshen Li, M.D · Changhai Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-05
Primary Completion
2020-12-05
Completion
2021-12-05

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03418584 on ClinicalTrials.gov